Year: 2025
Language: English
This resource is also available in:
This information sheet is designed to help understand the similarities, differences, and current state of knowledge for the existing genetic technologies for hemophilia.
The WFH does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals. For diagnosis or consultation on a specific medical problem, the WFH recommends that you contact your physician or local treatment centre. Before administering any products, the WFH urges patients to check dosages with a physician or hemophilia centre staff, and to consult the pharmaceutical company’s printed instructions.
The WFH does not promote any particular pharmaceutical product and any mention of any commercial brand in this presentation is strictly for educational purposes.
A summary of discussions held at the Fourteenth WFH Global Forum on Advances and Access to Safe Treatment Products for
Also Available In: English, Spanish, French, Arabic, Russian, Simplified Chinese This is not an official WFH translation. This resource has
The 3rd edition has also been translated into the following languages, with permission from the WFH, by NMOs/Other Organizations: Georgian,
A 3ª edição do Manual de Laboratório da WFH é o guia definitivo para o diagnóstico preciso da hemofilia e
The World Federation of Hemophilia (WFH) hosted an educational webinar titled “Progress toward a cure for hemophilia: gene editing explained”
A summary of discussions held at the Thirteenth WFH Global Forum on Advances and Access to Safe Treatment Products for